VIBATIV Drug Patent Profile

When do Vibativ patents expire, and what generic alternatives are available?

Vibativ is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in eighteen countries.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vibativ

Vibativ was eligible for patent challenges on September 11, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIBATIV

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	14
Patent Applications:	330
Drug Prices:	Drug price information for VIBATIV
What excipients (inactive ingredients) are in VIBATIV?	VIBATIV excipients list
DailyMed Link:	VIBATIV at DailyMed

See drug prices for VIBATIV

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIBATIV

NDA:

022110

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIBATIV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aaron Cook	Phase 4
Joseph L. Kuti, PharmD	Phase 4
Cumberland Pharmaceuticals, Inc.	Phase 4

See all VIBATIV clinical trials

Pharmacology for VIBATIV

Drug Class

Lipoglycopeptide Antibacterial

US Patents and Regulatory Information for VIBATIV

VIBATIV is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No				Y
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes				Y

Expired US Patents for VIBATIV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009

International Patents for VIBATIV

See the table below for patents covering VIBATIV around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	035333	GLUCOPEPTIDO SUSTITUIDO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, SU USO EN LA FABRICACION DE MEDICAMENTOS UTILES PARA TRATAR ENFERMEDADES BACTERIANAS Y METODO PARA PREPARAR DICHOS COMPUESTOS.
Austria	337334
Austria	388960

Supplementary Protection Certificates for VIBATIV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1292612	C300507	Netherlands		PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
1292612	CA 2011 00033	Denmark		PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
1292612	91908	Luxembourg		91908, EXPIRES: 20260501

VIBATIV (telavancin) Market Dynamics and Financial Trajectory: Sales Decline Drivers, Exclusivity Timeline, and Competitive Positioning

Last updated: July 27, 2026

VIBATIV (telavancin) has exited broad commercial scale in the US, with sales concentrated in acute-care settings and limited duration. The post-launch financial trajectory has been shaped by guideline positioning, safety label scrutiny in β-lactam–resistant and hospital-acquired/ventilator-associated pneumonia (HAP/VAP), competitive displacement from newer glycopeptides and lipopeptides, and the absence of sustained expansion into higher-volume indications. The economic profile is now driven less by growth and more by residual substitution in contracted formularies and tenders, with telavancin’s value proposition increasingly competed by alternatives with simpler safety monitoring and dosing logistics.

---

What is VIBATIV (telavancin) used for, and how do those indications shape market demand?

Featured answer: VIBATIV’s demand is tied to US hospital formularies for HAP and VAP and related resistant Gram-positive infections, with adoption constrained by safety considerations and narrow clinical use cases.

HAP/VAP and Gram-positive hospital infections: demand shape

Telavancin was positioned for serious Gram-positive infections, most notably:

• Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HAP/VAP), including cases involving methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant pneumococci in labeled settings.
• Skin and skin-structure infections (SSSI) in earlier development and labeling phases, depending on the final label scope at launch and subsequent label changes.

Market dynamic implication:
HAP/VAP sales are driven by ICU bed-days, culture-proven MRSA prevalence, and whether hospitals maintain telavancin on formulary when alternatives exist. Adoption is also sensitive to contracting patterns for high-cost antimicrobials.

Why telavancin’s usage pattern stays limited

Post-marketing and labeling-era frictions affect hospital decisions:

• Safety profile and monitoring requirements.
• Comparative efficacy perceptions relative to comparator classes (other glycopeptides and lipopeptides).
• Stewardship policies that prefer narrow-spectrum agents where feasible and reserve older/complex agents for resistant pathogens.

Commercial consequence:
Even when telavancin is clinically active, hospitals often choose drugs with fewer operational barriers or more favorable contracting economics.

---

How did VIBATIV sales perform after launch, and what does the financial trajectory show?

Featured answer: Telavancin’s commercial trajectory is characterized by peak adoption followed by sustained decline, consistent with a hospital-only antimicrobial niche facing ongoing competitive substitution.

Sales path typical for US acute-care specialty antimicrobials

For IV-only, hospital-administered antibiotics, sales usually follow three phases:

1. Rapid early adoption tied to high unmet need and clinician familiarity.
2. Formulary consolidation after data maturity and safety/monitoring standardization.
3. Sustained decline as competitors secure preferred positions and stewardship shifts prescribing.

VIBATIV’s observed market position aligns with phase 3.

Financial driver framework: what moved revenue

The main revenue levers for telavancin are:

• Dose penetration among eligible HAP/VAP patients.
• MRSA and resistant Gram-positive case mix in target hospitals.
• Formulary status (preferred vs restricted vs fallback).
• Tender and group purchasing organization pricing.
• Inventory turnover tied to antimicrobial stewardship and pre-authorization rules.

Core inference from the trajectory:
The market did not scale beyond a restricted hospital segment, and the competitive set prevented telavancin from retaining long-term shelf space.

---

What patent and exclusivity timelines affect VIBATIV’s commercial life in the US?

Featured answer: Telavancin’s exclusivity and patent estate structure has already allowed competitive pressure to grow over time, with the commercial endgame typical of complex IV antibiotics once key protection expires.

US exclusivity and regulatory exclusivity categories that matter

For small-molecule antibiotics, the commercial endpoint is typically governed by:

• Composition of matter patents
• Formulation and method-of-use patents
• Pediatric exclusivity, if any, and data exclusivity if applicable
• Orange Book “listed drug” patent inventory coverage for HAP/VAP and related uses

Commercial implication:
As key Orange Book-listed patents and exclusivity windows wind down, the threat of ANDA and Paragraph IV (for small molecules) increases. Even without immediate generic entry, investor and payer contracting expectations often shift pricing downward once sustained exclusivity ends.

---

What generic entry risks exist for telavancin, and how would they affect pricing and volumes?

Featured answer: Generic entry risk would compress gross-to-net through competitive acquisition pricing, faster bid cycles, and formulary status loss.

Paragraph IV and ANDA dynamics for hospital antibiotics

When generic threats become credible, three changes often follow:

• Hospitals reduce use of higher-cost incumbents when therapeutic interchange is operationally feasible.
• Group purchasing discounts for incumbent drugs erode to match benchmark prices.
• Merger or settlement dynamics can delay full erosion, but pricing downward pressure typically starts before final launch.

Pricing effect:
For IV hospital-only products, contract price reductions are usually larger than implied by small market share changes because pharmacy procurement is bid-based.

---

Which competitors displaced VIBATIV in HAP/VAP and MRSA hospital infections?

Featured answer: Telavancin competes in the IV hospital MRSA/Gram-positive space against other glycopeptides and lipopeptides, plus broader guideline shifts that favor alternatives when feasible.

Competitive set categories that influence formulary decisions

Key comparative competitors for MRSA HAP/VAP include:

• Other anti-MRSA glycopeptides (e.g., vancomycin-based strategies and newer glycopeptide derivatives depending on label eras and hospital guidelines)
• Lipopeptides with different safety and monitoring profiles (e.g., daptomycin for MRSA in off-label-adjacent or labeled settings depending on time frame and label scope)
• Newer or preferred MRSA regimens in stewardship algorithms

Why this matters commercially:
Hospitals pick the lowest friction option under procurement rules. Telavancin’s monitoring and safety label considerations increase the “administrative cost” of adoption even when clinical outcomes are comparable.

---

How does telavancin’s safety label scrutiny impact hospital prescribing and revenue?

Featured answer: Safety monitoring requirements reduce willingness to use telavancin early and increase restrictions during formulary reviews.

Practical hospital constraints

In IV antibiotics, prescribing decisions shift fast when safety requires additional steps:

• renal monitoring intensity
• contraindication handling
• extra lab cadence and adverse event management workflow

Commercial impact mechanism:
Even when telavancin is appropriate, stewardship teams may constrain use to:

• culture-confirmed resistant pathogens
• patients who cannot receive preferred alternatives
• cases where local antibiograms justify the risk-benefit

This leads to limited patient pools and lower dose penetration over time.

---

What is the Orange Book status of VIBATIV, and how does it map to remaining enforceable IP?

Featured answer: Orange Book listings for telavancin define the patent-led enforceability landscape for generic or biosimilar-adjacent entry risk. The commercial decline narrative is consistent with long-tail expiration and settlement/competition effects.

What Orange Book coverage typically means for market dynamics

Orange Book-listed patents typically include:

• composition of matter
• methods of use
• formulations or manufacturing process claims

Business implication:
When independent composition claims expire, even if method patents remain, challengers can focus litigation on the remaining claims, resulting in delayed but still pressure-driven price erosion.

---

How do contracting and payer dynamics affect VIBATIV net sales versus list price?

Featured answer: In hospital antibiotics, revenue depends more on contracting mechanics and rebates than on headline list pricing.

What drives VIBATIV net revenue in acute-care procurement

• Group purchasing organization (GPO) pricing and bid outcomes
• Hospital formulary tiering (preferred vs non-preferred)
• Pharmacy benefit manager (PBM) and hospital pharmacy rebate structures
• Utilization management and stewardship restrictions
• ADR and substitution policies under which pharmacists switch to preferred alternatives

Financial trajectory link:
Once competitive drugs secure preferred tier status, telavancin pricing must adjust to win “fallback” usage. That compression lowers gross-to-net even with stable prescription counts.

---

What litigation, settlements, and branded competitor behavior affect telavancin’s market?

Featured answer: Patent litigation and settlement terms typically influence timing of generic pressure and the scope of competitive substitution.

How patent disputes translate into market outcomes

In hospital antibiotic segments, IP events influence:

• launch timing expectations
• incumbent pricing and contracting strategy
• hospital willingness to switch inventory ahead of label or guideline changes

Commercial reality:
Even absent immediate generic launches, litigation risk can trigger procurement renegotiation. Hospitals use competitive pressure to secure better pricing from the branded incumbent.

---

How does VIBATIV’s performance compare with other hospital IV antibiotics in the same era?

Featured answer: Telavancin’s financial trajectory is consistent with late-cycle branded IV hospital antibiotics that face rapid payer and formulary switching once safer or simpler alternatives gain preferred status.

Key comparative dimensions that usually decide winners

• dosing simplicity and monitoring burden
• safety and contraindication clarity
• availability of clinical pathways and stewardship acceptance
• procurement economics and rebate structures
• breadth of labeled indications and confidence in guideline fit

Implication for telavancin:
When competitors offered equal or better perceived value with less operational burden, telavancin lost volume, not just share.

---

Key market dynamics summary for VIBATIV (telavancin)

Commercial drivers pushing sales down

• Restricted patient pools in HAP/VAP versus broader outpatient markets
• Safety label scrutiny and monitoring requirements
• Guideline and stewardship-driven substitution
• Competitive displacement by other IV anti-MRSA options
• Contracting and tender pricing compression over time

Commercial inhibitors that limit rebound

• Narrower sustained expansion opportunities
• Hospital formularies favoring preferred tier products
• Operational friction relative to simpler regimens

---

Key Takeaways

• VIBATIV’s market is structurally hospital-only and depends on HAP/VAP case mix, MRSA prevalence, and formulary placement.
• The financial trajectory aligns with a branded IV antimicrobial pattern: early adoption followed by sustained decline as competitive and safety/operational factors shift hospital preference.
• Revenue erosion is driven by contracting economics, tiering loss, and stewardship restrictions, not just patent expiry.
• Generic entry and patent litigation events would primarily accelerate pricing compression and substitution, reducing incumbent net sales even before full launch.

---

FAQs

1) What determines telavancin formulary inclusion in HAP/VAP hospitals?

Formulary inclusion depends on patient eligibility criteria, MRSA antibiogram relevance, safety monitoring feasibility, and contract pricing outcomes with preferred alternatives.

2) How do adverse events and renal monitoring requirements affect telavancin adoption?

They increase operational burden for infection control teams and reduce comfort for empiric or broader use, shifting telavancin toward restricted fallback prescribing.

3) When do patent expirations typically stop branded volume recovery for IV hospital antibiotics?

Once composition-of-matter and key Orange Book patents expire or lose enforceability, generic threat triggers procurement renegotiation and formulary tier changes that drive sustained volume loss.

4) What hospital purchasing mechanisms most directly impact VIBATIV net sales?

GPO bids, group contracting, and hospital rebate structures typically determine net price more than list price.

5) Which infection control and stewardship trends most influence telavancin demand?

Preference for agents with simpler monitoring, tightened empiric use rules, and MRSA stewardship pathways reduce telavancin’s eligible patient pool over time.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (telavancin / VIBATIV listings). FDA.
2. FDA label and regulatory documents for VIBATIV (telavancin). U.S. Food and Drug Administration. (n.d.).
3. Drug approval and labeling history records for telavancin. U.S. Food and Drug Administration. (n.d.).